Related Experiment Video
Updated: Mar 6, 2026

Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient
Juan Li1,2, Jie Liu1,2, Zheyong Liang1,2
1Center for Translational Medicine, The First Affiliated Hospital of Xian Jiaotong University, Xi'an 710061, Shaanxi, China.
Abstract:
Loss or dysfunction of tumor suppressor retinoblastoma (RB) is a common feature in various tumors, and contributes to cancer cell stemness and drug resistance to cancer therapy. However, the strategy to suppress or eliminate Rb-deficient tumor cells remains unclear. In the present study, we accidentally found that reduction of DNA replication licensing factor MCM7 induced more apoptosis in RB-deficient tumor cells than in control tumor cells. Moreover, after a drug screening and further studies, we demonstrated that statin drug Simvastatin and Atorvastatin were able to inhibit MCM7 and RB expressions. Further study showed that Simvastatin and Atorvastatin induced more chromosome breaks and gaps of Rb-deficient tumor cells than control tumor cells. In vivo results showed that Simvastatin and Atorvastatin significantly suppressed Rb-deficient tumor growth than control in xenograft mouse models. The present work demonstrates that 'old' lipid-lowering drugs statins are novel weapons against RB-deficient tumors due to their effects on suppressing MCM7 protein levels.
Insights
Statins like Simvastatin and Atorvastatin effectively target retinoblastoma (RB)-deficient tumors by reducing MCM7 levels, inducing cancer cell death and inhibiting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Loss or dysfunction of the retinoblastoma (RB) tumor suppressor is common in cancers, promoting stemness and therapy resistance.
- Effective strategies to eliminate RB-deficient tumor cells are currently unclear.
Purpose of the Study:
- To identify novel therapeutic strategies for RB-deficient tumors.
- To investigate the effects of MCM7 reduction on RB-deficient cancer cells.
Main Methods:
- Drug screening to identify compounds affecting RB-deficient cells.
- Assessing the impact of statins (Simvastatin, Atorvastatin) on MCM7 and RB expression.
- Evaluating chromosome stability and tumor growth in xenograft mouse models.
Main Results:
- Reducing MCM7 induced apoptosis in RB-deficient tumor cells.
- Statins inhibited both MCM7 and RB expression.
- Statins caused more chromosome damage in RB-deficient cells and suppressed tumor growth in vivo.
Conclusions:
- Statins represent a novel therapeutic approach against RB-deficient tumors.
- The anti-tumor effect of statins is linked to MCM7 suppression.
Related Concept Videos
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity

